Recently, Yoshioka and colleagues showed that HER2-positive gastric cancers are sensitive to pan-HER inhibitors, such as neratinib and lapatinib [34], suggesting that combing neratinib with an anti-HER2 mAb may be a better therapeutic strategy for the treatment of HER2-positive gastric cancer. This evidence concerns the gene ERBB2 and gastric cancer.